(36MTHS) A Phase 1B Trial to Determine the Immunogenicity and Tolerability of Extended Schedule Vaccination with MVA-EBNA1/LMP2 for Patients with EBV+ Nasopharyngeal Carcinoma

Project Details

Short title(36MTHS) A Phase 1B Trial to Determine the Immunogenicity and Tolerability of Extended Schedule Vaccination with MVA-EBNA1/LMP2 for Patients with EBV+ Nasopharyngeal Carcinoma
StatusFinished
Effective start/end date1/01/12 → 31/08/16

Funding

  • Cancer Research UK